Loading stock data…
ALX Oncology Holdings Inc (ALXO)
$2.17+0.13 (+6.62%)
Market OpenUpdated 2:08 PM EDT
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ALX Oncology Holdings Inc. in the Healthcare sector is trading at $2.17 with a market capitalization of $200M. Wall Street consensus targets $4.60 (5 analysts), implying a +111.5% move over the next 12 months. The stock is currently 18% below its 52-week high of $2.66, remaining 27.2% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +111.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$18.97M↑ | -$23.02M↓ | -$22.53M↑ | -$23.47M↑ | -$31.82M |
| Net Income | -$17.93M↑ | -$22.85M↓ | -$22.14M↑ | -$25.95M↑ | -$30.75M |
Peer Comparison
JNJUNHPFE
Fundamentals
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$200.50M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-58.72%
Volume
Today's trading volume
1.62M
Recent News
ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs
ALX Oncology (NASDAQ:ALXO) executives said the company is focused on advancing two clinical-stage oncology programs, with upcoming data readouts expected to shape potential later-stage development plans for its lead CD47 program, evorpacept, and its EGFR-targeted antibody-drug conjugate, ALX2004. S
ALX Oncology (ALXO) Q1 2026 Earnings Transcript
Most notably, we are very excited to share with you the data set that was presented yesterday in Munich at ESMO Breast 2026 from the analysis of our trial evaluating evorpacept and zanidatamab, which clearly showed again that CD47 expression is a key predictive biomarker for increasing durable clinical response in heavily pretreated HER2-positive patients. This further validates the results we saw with Evo and HER2-positive gastric cancer from our ASPEN-6 trial.
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
ALX Oncology Holdings Inc. Q1 2026 Earnings Call Summary
Moby summary of ALX Oncology Holdings Inc.'s Q1 2026 earnings call
ALX Oncology Q1 Earnings Call Highlights
ALX Oncology (NASDAQ:ALXO) executives used the company’s first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its EGFR-targeted antibody-drug conjugate program, ALX2004. CEO Jason Lettmann said the quarter featured “continue